GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

160.9B

Vuru Grade

75.00/100

Current Price

$106.45
-1.06 (-0.99%)

Growth Price

$26.98
Overvalued by 74.66%

Stability Price

$15.14
Overvalued by 85.77%

Company Metrics

  • 24.36 P/E
  • 9.32 P/S
  • 10.17 P/B
  • 4.414 EPS
  • 39.33% Cash ROIC
  • 0.34 Cash Ratio
  • 0 / 0% Dividend
  • 13.69M Avg. Vol.
  • 1.69B Shares
  • 160.9B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

There is no news available at this time.